Sucralfate
Generic Name: sucralfate
Brand Names:
Sucralfate
DESCRIPTION Sucralfate tablets, USP contain sucralfate USP and sucralfate is an α-D-glucopyranoside, β-D fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. Tablets for oral administration contain 1 g of sucralfate, USP. Also contain: magnesium stearate, microcrystalline cellulose, and corn starch. Therapeutic category: antiulcer. figure
Overview
DESCRIPTION Sucralfate tablets, USP contain sucralfate USP and sucralfate is an α-D-glucopyranoside, β-D fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. Tablets for oral administration contain 1 g of sucralfate, USP. Also contain: magnesium stearate, microcrystalline cellulose, and corn starch. Therapeutic category: antiulcer. figure
Uses
INDICATIONS AND USAGE Sucralfate tablets are indicated in: • Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
Dosage
DOSAGE AND ADMINISTRATION Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach. Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day.
Side Effects
ADVERSE REACTIONS Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2,700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth Dermatological: pruritus, rash Nervous System: dizziness, insomnia, sleepiness, vertigo Other: back pain, headache Post-marketing cases of hypersensitivity have been reported with the use of sucralfate tablets, including dyspnea, lip swelling, pruritus, rash, and urticaria.
Warnings
CONTRAINDICATIONS Sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
Storage
HOW SUPPLIED Sucralfate tablets USP, 1g are supplied as follows: NDC 688778-8779-3 in bottles of 30 tablets with child-resistant closure NDC 688778-8779-9 in bottles of 100 tablets with child-resistant closure White to off-white, capsule shaped, biconvex, scored, uncoated tablets, debossed with "6" and "75" on either side of score and plain on other side.
Frequently Asked Questions
What is Sucralfate used for?▼
INDICATIONS AND USAGE Sucralfate tablets are indicated in: • Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
What are the side effects of Sucralfate?▼
ADVERSE REACTIONS Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2,700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth Dermatological: pruritus, rash Nervous System: dizziness, insomnia, sleepiness, vertigo Other: back pain, headache Post-marketing cases of hypersensitivity have been reported with the use of sucralfate tablets, including dyspnea, lip swelling, pruritus, rash, and urticaria.
What are the important warnings for Sucralfate?▼
CONTRAINDICATIONS Sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
Related Medications
Velpatasvir Sdd
velpatasvir sdd
Dosage form: POWDER. Active ingredients: VELPATASVIR (1 kg/kg). Category: BULK INGREDIENT.
Flex Drops
flex drops
*Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.
Tafamidis (cc)
tafamidis (cc)
Dosage form: POWDER. Active ingredients: TAFAMIDIS (35 kg/35kg). Category: BULK INGREDIENT.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.